FDA OKs Drug's Expanded Role
By Staff & AP Reports
Work continues on the $600 million expansion at Genentech's Vacaville manufacturing facility. (Courtesy photo)
The breast cancer drug Herceptin - one of the drugs manufactured at Genentech's Vacaville facility - received expanded federal approval Thursday to include treatment of some women after they have undergone surgery.
In two clinical trials, women given the drug along with chemotherapy had fewer relapses in the three years after surgery - either to remove a lump or the whole breast - than those just given standard chemotherapy, the Food and Drug Administration said in announcing the additional approval.
Frank Jackson, vice president and general manager of Vacaville product operations, has told The Reporter that the positive results and growth of products such as Herceptin, "is driving demand for additional manufacturing capacity from Genentech, and Vacaville's role is to be a significant supplier for these extra runs." The Vacaville plant is currently undergoing an expansion that will greatly increase its manufacturing capacity.
Herceptin is only for the estimated 20 percent of patients whose breast tumors churn out too much of a protein known as HER-2. About 50,000 women in the United States and 250,000 worldwide are diagnosed with this type, called HER-2 positive, each year.
In 1998, the FDA approved Herceptin to treat breast cancer after it had spread to other parts of the body. Thursday's approval expands its use to women with cancer in the breast or lymph nodes that has been surgically removed, the FDA said.
The most serious side effect of Herceptin is heart failure. Only patients with HER-2 positive tumors, and who do have heart failure or a weak heart, should be given the drug, also known as trastuzumab.
- ► 2007 (799)
- $5.1 MILLION TO FUND AG HEALTH AND SAFETY CENTER A...
- WEST VILLAGE DEVELOPMENT CROSSES LATEST HURDLE
- County Economic Summit Planned
- Solano Competing for Big Transportation Dollars
- City OKs Marina Project Accord
- A Jewel for Cordelia
- Sutter, NorthBay, Kaiser to Revamp Fairfield Facil...
- Suisun to Negotiate for Entertainment Boat
- Stem Cell Loans Advance
- Buyers Market Strengthens on Fewer Home Sales
- Campus in Vallejo Shaping Up Well
- Helpful Herceptin
- From Vacant to Vibrant
- Tanner Named City Manager
- UC DAVIS WEST VILLAGE DEVELOPMENT CROSSES LATEST H...
- Genentech breast-cancer drug gets FDA OK - Sacrame...
- Regents approve UC Davis' West Village project - S...
- Valley unemployment rate down to 4.2% - Silicon Va...
- Home Prices Stabilize, but Sales Slump
- Council Backs Grants For Aid To Downtown
- Big Business Deals Head to Vacaville
- East Bay home sales down more than 20% - East Bay ...
- UC Davis agricultural center gets funding renewal ...
- Home sales, prices continue to fall - Sacramento B...
- Travis Credit Union's Van Ouwerkerk named credit u...
- Women make up less than 10 percent of California e...
- BIRDS LANDING, SOLANO COUNTY / New windmills near ...
- New Electricity is Blowing in Solano's Winds
- City Council OKs Wal-Mart Impact Study
- Dixon Downs Gets Final OK From Council
- Tenants Fill Up Nut Tree Spaces
- Suisun Hopes to Start on Hotel Before Summer
- Biotech Giant's First Big Buy
- Suisun City Considers Reservations For a New Hotel...
- 'Critical Link' to Relieve Congestion
- Ready to Take Off
- Welcome Results for Business
- OK of Prop 1A Will Aid Solano
- Water Agency Unveils Guide to Regulations
- Solano County, 90 modern wind turbines churn out 1...
- Oakland ice creamery Fentons to open second shop i...
- Vallejo Council to consider university village con...
- Travis way station offers care, nurturing
- Vacaville Overpasses are Link to Economic Developm...
- Freshman enrollment up 25 percent at UC Davis - sa...
- The California Aggie - UCDMC plans to open stem ce...
- On the Road to Transit
- Nut Tree Sprouting More Firms
- ▼ November (48)
- ► 2005 (627)
- ► 2004 (125)